gdc
Lung Cancer

A Welcomed Mutation? Don Cook Is Living One Day at a Time with ALK-Positive Lung Cancer

Don Cook felt he had a second chance at life when he learned that his lung cancer had a genetic alternation known as ALK mutation, for which targeted therapies are available today.
November 2018 Volume 4 – Lung Cancer
Kelsey Moroz

It was Friday afternoon around 3 o’clock when the phone in Don and Diana Cook’s living room rang. The person on the other end had only one thing to say—Don’s non–small-cell lung cancer, or NSCLC, had tested positive for the genetic ALK mutation (genetic abnormality). As Don hung up the phone, his family ran around the house in celebration.

Share this:

Recommended For You
Lung CancerIssue Introductions
Looking at Lung Cancer without Stigma
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
In her introduction to this special issue on Lung Cancer, Lillie emphasizes that we need to inspire and help people to stop smoking, and get rid of the overall stigma surrounding this disease.
Patient StoriesLung CancerPatient Advocacy
Becoming a Patient Advocate After a Small-Cell Lung Cancer Diagnosis at Age 28
By Montessa Lee
Montessa Lee’s pain persisted after an initial visit to the doctor and a misdiagnosis. Finally, an x-ray in the emergency room revealed a 15-cm mass on her left lung. Read how she turned anger into action.
Lung CancerImmunotherapyBiomarkers
Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
By Wayne Kuznar
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC.
FDA Approvals, News & UpdatesLung Cancer
Tecentriq First Immunotherapy Approved for Adjuvant Treatment of Patients with Early-Stage NSCLC and PD-L1 Expression
On October 15, 2021, the FDA approved a new indication for Tecentriq (atezolizumab) for adjuvant (additional) treatment of patients with stage II-IIIA non–small-cell lung cancer and PD-L1 expression, after surgical removal of the tumor and chemotherapy. This is the first immunotherapy approved for patients with early-stage lung cancer.
Last modified: June 22, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest